Characterization of receptor-mediated signal transduction by Escherichia coli type IIa heat-labile enterotoxin in the polarized human intestinal cell line T84.
Escherichia coli type IIa heat-labile enterotoxin (LTIIa) binds in vitro with highest affinity to ganglioside GD1b. It also binds in vitro with lower affinity to several other oligosialogangliosides and to ganglioside GM1, the functional receptor for cholera toxin (CT). In the present study, we characterized receptor-mediated signal transduction by LTIIa in the cultured T84 cell model of human intestinal epithelium. Wild-type LTIIa bound tightly to the apical surface of polarized T84 cell monolayers and elicited a Cl(-) secretory response. LTIIa activity, unlike CT activity, was not blocked by the B subunit of CT. Furthermore, an LTIIa variant with a T14I substitution in its B subunit, which binds in vitro to ganglioside GM1 but not to ganglioside GD1b, was unable to bind to intact T84 cells and did not elicit a Cl(-) secretory response. These findings show that ganglioside GM1 on T84 cells is not a functional receptor for LTIIa. The LTIIa receptor on T84 cells was inactivated by treatment with neuraminidase. Furthermore, LTIIa binding was blocked by tetanus toxin C fragment, which binds to gangliosides GD1b and GT1b. These findings support the hypothesis that ganglioside GD1b, or possibly a glycoconjugate with a GD1b-like oligosaccharide, is the functional receptor for LTIIa on T84 cells. The LTIIa-receptor complexes from T84 cells were associated with detergent-insoluble membrane microdomains (lipid rafts), extending the correlation between toxin binding to lipid rafts and toxin function that was previously established for CT. However, the extent of association with lipid rafts and the magnitude of the Cl(-) secretory response in T84 cells were less for LTIIa than for CT. These properties of LTIIa and the previous finding that enterotoxin LTIIb binds to T84 cells but does not associate with lipid rafts or elicit a Cl(-) secretory response may explain the low pathogenicity for humans of type II enterotoxin-producing isolates of E. coli.
Wimer-Mackin
S
S
Combined Program in Pediatric Gastroenterology and Nutrition, Children's Hospital, and Harvard Medical School, Boston, Massachusetts 02115, USA.
Holmes
R K
RK
Wolf
A A
AA
Lencer
W I
WI
Jobling
M G
MG
D001427:Bacterial Toxins / Q000378:metabolism*; D002460:Cell Line; D016764:Cell Polarity / Q000502:physiology*; D002712:Chlorides / Q000378:metabolism; D004768:Enterotoxins / Q000378:metabolism*; D004926:Escherichia coli / Q000472:pathogenicity; D029968:Escherichia coli Proteins; D005677:G(M1) Ganglioside / Q000378:metabolism; D005732:Gangliosides / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006801:Humans; D007413:Intestinal Mucosa / Q000166:cytology / Q000378:metabolism*; D009439:Neuraminidase / Q000494:pharmacology; D011956:Receptors, Cell Surface / Q000037:antagonists & inhibitors / Q000378:metabolism*; D015398:Signal Transduction; D013744:Tetanus Toxin / Q000494:pharmacology
D001427:Bacterial Toxins; D002712:Chlorides; D004768:Enterotoxins; D029968:Escherichia coli Proteins; D005732:Gangliosides; D011956:Receptors, Cell Surface; D013744:Tetanus Toxin; C023552:choleragen receptor; C033851:ganglioside, GD1b; D005677:G(M1) Ganglioside; C027538:heat-labile enterotoxin, E coli; D009439:Neuraminidase